Press Releases
Amgen R&D Executive David Reese to Lead CEO Roundtable on Cancer Board
Directors of the CEO Roundtable on Cancer have elected David M. Reese, MD, Executive Vice President of Research and Development at Amgen, to a two-year term as Board Chairman effective immediately.
Published On: March 10, 2023
COMMITMENT TO HEALTH RECOGNIZED AT TWILIO, KOCH INDUSTRIES, MEHARRY MEDICAL COLLEGE, SOUTH CAROLINA STATE UNIVERSITY AND STILLMAN COLLEGE
The CEO Roundtable on Cancer is recognizing two companies and three universities for their commitment to the health of employees, students and community members with CEO Cancer Gold Standard™ accreditation.
Published On: December 20, 2022MD Anderson, Merck, Major General Elder Granger Honored for Contributions to Cancer Research, Eliminating Health Disparities
MD Anderson received the 2022 Charles A. Sanders Life Sciences Award at the CEO Roundtable’s Annual Meeting and Conference on Nov. 1. Merck and Dr. Granger each were honored with the Spirit of Health Award.
Published On: November 22, 2022Alphanumeric Systems, Jasper Health, Shaw University Recognized for Commitment to Health
Three new companies have earned CEO Cancer Gold Standard accreditation from the CEO Roundtable on Cancer, recognizing their focus on building a healthier workplace by focusing on cancer risk reduction, early detection, access to clinical trials, and high-quality care.
Published On: July 20, 2022Elligo Health Research®, Black Diamond Therapeutics, Change Healthcare, Jasper Health, B&C International Join CEO Roundtable on Cancer to Reduce Cancer’s Toll
Five new companies have joined the CEO Roundtable on Cancer and its campaign to do something more about cancer prevention, diagnosis, and treatment for their employees, their families, and their communities.
Published On: July 12, 2022CEO Roundtable on Cancer Names William Louv Chief Executive Officer, Elects Amgen’s R&D Leader David Reese, Major General Elder Granger Directors
The CEO Roundtable on Cancer (CEORT) Board of Directors today announced that William C. Louv, PhD, will lead the organization as Chief Executive Officer effective immediately, and it has elected two new Directors: David M. Reese, MD, Executive Vice President of R&D at Amgen, and Major General Elder Granger, MD, President and CEO of THE 5Ps, LLC.
Published On: June 14, 2022Amgen CEO Bradway, Former Glaxo Wellcome CEO Ingram, B&C Associates Inc. CEO Brown Recognized
Charles A. Sanders Award presented to Amgen and CEO Robert A. Bradway and former Glaxo Wellcome CEO Robert A. Ingram;.Spirit of Health Award goes to B&C Associates Inc. Founder and CEO Robert J. Brown.
Published On: February 4, 2022CEO Roundtable on Cancer Launches “Going for Gold” Initiative to Advance Equitable Cancer Care
Collaboration with HBCUs, HSIs, Merck, Amgen and SAS Elevates Cancer Prevention, Diagnosis, Quality Treatment Addressing Disparities in Health
Published On: January 13, 2022
New consensus disease definitions to aid care, accelerate research for cancer patients with side effects from immunotherapies
A paper outlining consensus disease definitions for neurological toxicities in cancer patients undergoing immune checkpoint inhibitor treatment was published this week in the Journal for ImmunoTherapy of Cancer (JITC) by a team of physicians at 16 institutions. Neurologists and oncologists at Massachusetts General Hospital with support from scientists at Project Data Sphere® led the team to deliver the first consensus-based definitions of disease and severity criteria for any immune-related toxicity.
Published On: July 28, 2021